CAPR
Capricor·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
EPS Beats Expectation
RSI Overbought
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CAPR
Capricor Therapeutics, Inc.
A company that developing regenerative medicine and large molecule products to treat heart failure
10865 Road to the Cure, Suite 150, San Diego, California 92121
--
Capricor Therapeutics, Inc., is incorporated in Delaware. The Company is a clinical-stage biotechnology company focused on developing transformational cell and exosome-based therapies for the treatment of Duchenne muscular dystrophy (" DMD "), a rare form of muscular dystrophy that leads to muscle degeneration and premature death, as well as a disease with high unmet medical needs.
Earnings Call
Q1/2025
Estimate EPS-0.32
Actual EPS-0.53
Estimate Revenue3.16M
Actual Revenue0
Contradictions Unveiled: Insights from the Latest Deramiocel Earnings Call on Launch Timelines, AdCom Expectations, and Manufacturing Readiness
May 20,2025 12:28
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.54
Actual EPS-0.54
Estimate Revenue480.00K
Actual Revenue0
Capricor's Q3 2025: Contradictions Emerge on HOPE-3 Data, FDA Flexibility, and Potency Assays
Nov 10,2025 11:43
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CAPR has released its 2025 Q3 earnings. EPS was reported at -0.54, versus the expected -0.54, meeting expectations. The chart below visualizes how CAPR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
